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Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab
in the Treatment of Patients with Extensive-Stage
Small-Cell Lung Cancer
David R. Spigel, MD,*† F. Anthony Greco, MD,*† John D. Zubkus, MD,† Patrick B. Murphy, MD,†
Ruben A. Saez, MD,‡ Cindy Farley, CCRP,* Denise A. Yardley, MD,*† Howard A. Burris, III, MD,*†
and John D. Hainsworth, MD*†
Introduction: Bevacizumab’s role in the treatment of small cell
lung cancer (SCLC) is unknown. A multicenter phase II trial with
bevacizumab plus chemotherapy was conducted in patients with
untreated extensive-stage SCLC.
Methods: Eligibility: no prior SCLC chemotherapy, no active brain
metastases, no hemoptysis, and Eastern Cooperative Oncology
Group performance status 0–1. Treatment consisted of irinotecan
(60 mg/m2) administered intravenously (IV) on days 1, 8, 15;
carboplatin area under the concentration-time curve  4, IV, on day
1; bevacizumab (10 mg/kg, IV) on days 1 and 15 every 28 days for
up to six cycles. Restaging was performed every two cycles (8
weeks). Patients with no progression received maintenance bevaci-
zumab. Primary end point is 40% improvement in historical median
time to progression (TTP) of 6 months.
Results: Fifty-one patients were enrolled from February 2006 to
March 2007 (22-month median follow-up). Baseline features: me-
dian age 66 years (range 46–81 years); male 57%; and Eastern
Cooperative Oncology Group performance status 0–1 33/67%. Ob-
jective response rate 84% (95% CI 71–93%): 1 complete and 42
partial responses. Two patients (4%) had stable disease, and two
patients had progressive disease. Four patients were unassessable
because of treatment-related toxicity. Median TTP was 9.13 months
(95% CI 7.36–9.46 months). Median overall survival was 12.1
months (95% CI 9.6–13.5 months); 1- and 2-year overall survivals
were 51 and 14%, respectively. Grade 3/4 toxicity (10%): neutro-
penia (39%), thrombocytopenia (22%), dehydration (10%), diarrhea
(31%), fatigue (20%), and pulmonary symptoms (10%). No signif-
icant bleeding occurred.
Conclusions: In this phase II trial, irinotecan, carboplatin, and
bevacizumab achieved response, TTP, and survival outcomes that
compare favorably with larger randomized trials using chemother-
apy alone. Randomized trials can best assess bevacizumab’s impact
in the first-line treatment of extensive-stage SCLC.
Key Words: Small cell lung cancer, Bevacizumab, First line,
Irinotecan, Carboplatin.
(J Thorac Oncol. 2009;4: 1555–1560)
Approximately, 20,000 people are diagnosed with smallcell lung cancer (SCLC) annually in the United States.
Less than 5 to 10% of patients diagnosed with extensive-stage
SCLC (ES-SCLC) will survive 2 years.1 This poor outcome
persists despite the high response rates seen with modern
chemotherapy.2–4 Newer treatment approaches are needed.
One such treatment strategy in other solid tumors has
been to target angiogenesis by incorporating bevacizumab, a
monoclonal antibody to vascular endothelial growth factor,
into standard chemotherapy regimens. In randomized trials,
bevacizumab has been shown to improve survival in patients
with metastatic colorectal cancer and advanced non-small cell
lung cancer, and progression-free survival in women with
metastatic breast cancer, when combined with chemotherapy.5–7
Bevacizumab may also play an important role in SCLC where
preclinical models suggest angiogenesis is an important fac-
tor in tumor growth.8–10
We previously completed a phase II trial in patients
with limited-stage SCLC using bevacizumab as maintenance
therapy following primary treatment with carboplatin, irino-
tecan, and concurrent radiation.11 Previous studies by our
center and others have shown carboplatin and irinotecan to be
well tolerated and active in SCLC.12–16 In the limited-stage
trial, bevacizumab did not seem to add benefit when used as
a single agent following combination therapy. We report on a
subsequent multicenter phase II trial where bevacizumab was
incorporated with carboplatin and irinotecan from the start of
treatment in patients with ES-SCLC.
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PATIENTS AND METHODS
This trial was initiated in February 2006. Participating
centers included the Sarah Cannon Research Institute and
select sites from the Sarah Cannon Oncology Research Con-
sortium, a national community-based research network (see
Appendix).
Patients
Patients with histologically confirmed SCLC were en-
rolled. Patients with extensive-stage disease were eligible.
This included patients with stage IIIB and IV disease by the
TNM system. Patients with large-cell neuroendocrine tumors
or mixed small cell and non-small cell histologies were
ineligible. Patients had measurable disease per RECIST.17
Other eligibility criteria included: age 18 years; no prior
chemotherapy, primary radiation, or biologic treatment; ab-
sence of active brain metastases (i.e., definitively treated with
radiation and surgery); Eastern Cooperative Oncology Group
(ECOG) performance status (PS) 0–1 (ranging from normal
to ambulatory, but restricted in strenuous activity); adeuate
organ function (defined as absolute neutrophil count ANC
1.5  109/liter, platelet count 100  109/liter, serum
bilirubin 3 mg/dL, serum AST and ALT 3  the upper
limit of normal, and serum creatinine 1.6 mg/dL).
Exclusion criteria included major surgery within 4
weeks of treatment; major bleeding, hemoptysis, coagulopa-
thy, or need for therapeutic anticoagulation; proteinuria more
than 500 mg/24 h; pregnancy or lactation; clinically signfi-
cant cardiovascular disease; medically uncontrolled hyperten-
sion; and prior malignancy within 3 years except nonmela-
noma skin cancer and cervical carcinoma in situ. All patients
provided written informed consent before enrollment.
Pretreatment Evaluation
Before treatment patients were evaluated by history,
physical examination, and laboratory testing. Baseline tumor
staging was performed using computerized tomography (CT)
scans of the chest and abdomen, CT or magnetic resonance
imaging of the brain, and bone scan or positron emission
tomography.
Treatment Plan
All patients received carboplatin at a dose calculated to
produce an area under the concentration-time curve (AUC,
4.0 mg/ml/min) administered intravenously (IV) on day 1 and
irinotecan (60 mg/m2, IV) on days 1, 8, and 15, every 28 days
for a maximum of six cycles (Fig. 1). The carboplatin dose
was calculated using the method described by Calvert et al.18
and was found to be well tolerated and efficacious when
delivered on a 3 to 4 week schedule in a previous study from
our center.16 Bevacizumab (10 mg/kg) was administered
intravenously on days 1 and 15 every 28 days (1 cycle).
Patients were restaged with CT scans every two cycles (per
RECIST). If there was no evidence of disease progression or
significant toxicity after six cycles patients continued to
receive maintenance bevacizumab (same dose and schedule)
for an additional 6 months with restaging every 2 months.
Dose modifications were based on ANC and platelet
counts on day 1 of each cycle, and doses were not increased
once modified. No adjustments were required if the ANC was
1.5  109/liter and platelet count 100  109/liter. If the
ANC was 1.0 to 1.49  109/liter or platelets 75 to 99 
109/liter, chemotherapy was reduced to 25%. If the ANC was
less than 1.0  109/liter or platelets less than 75  109/liter,
chemotherapy was held until counts recovered to baseline
parameters when chemotherapy could be resumed with a 25%
dose reduction. If the counts did not recover within 3 weeks the
patient came off study. Patients requiring hospitalization for
neutropenia and fever had 25% dose reductions. Chemotherapy
was also reduced to 25% for grade 3/4 nonhematologic toxicity.
Loperamide was used for all grades of diarrhea.
Bevacizumab was held for nonpulmonary or noncentral
nervous system bleeding, and grade 3 congestive heart failure
or proteinuria. Bevacizumab was stopped permanently for
uncontrolled hypertension; pulmonary, central nervous sys-
tem, or unresolved or severe bleeding otherwise, grade 4
congestive heart failure or proteinuria, bowel perforation or
wound dehiscence, any thromboembolic event, or any treat-
ment delay more than 28 days.
Toxicity assessments were made according to the com-
mon terminology criteria for adverse events (CTCAE version
3.0) of the National Cancer Institute. Cytokines were not
administered with the first course of treatment; however,
prophylactic granulocyte colony-stimulating factor for pa-
tients experiencing febrile neutropenia was permitted at the
discretion of the treating physician and was not to substitute
for mandated dose reductions. Routine antiemetics were used
as premedication.
This trial was approved by the institutional review boards
of all participating institutions and was conducted in accordance
with the Declaration of Helsinki, current Food and Drug Ad-
ministration Good Clinical Practices, and local ethical and legal
requirements. The Sarah Cannon Research Institute designed
and coordinated the trial and was responsible for all aspects of
data collection and analysis. The authors made the decision to
publish the data. The authors assume responsibility for the
overall content and integrity of the manuscript and vouch for the
accuracy and completeness of the reported data. Bevacizumab
(Cancer Chemotherapy National Service Center code 704865)
was provided by Genentech. Commercially available forms of
chemotherapy were used.
FIGURE 1. Trial schema illustrating protocol treatment plan.
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Definition of Response
All patients were evaluated for response by RECIST
criteria. The final response category assigned represented the
best response obtained during treatment.
Statistical Methods
The primary objective of this phase II study was to
assess the median time to progression (TTP). Secondary
objectives were to assess the objective response rate, median
overall survival (OS), and treatment-related toxicity. The
sample size was based on the assumption that 50% of patients
will be without disease progression at 6 months with standard
first-line chemotherapy. It was hypothesized that bevaci-
zumab would improve the 6-month TTP by 40%. Fifty
patients were required to demonstrate this improvement with
a power of 80% and alpha level of 0.05. Efficacy outcomes
were based on intent-to-treat analyses. TTP was defined as
the interval between the start date of treatment and the date of
occurrence of progressive disease. OS was measured from the
date of study entry until the date of death. If there was
intolerable toxicity or discontinuation of treatment secondary
to toxicity, the patient was considered assessable, but was
classified as a treatment failure. If other cancer therapy was initiated
before progressive disease occurred, the patient was censored
on the date on which the other therapy began. If a patient was
lost to follow-up, the patient was censored on the date of last
contact. Survival curves were constructed using Kaplan-
Meier method.19
Toxicity was evaluated in all patients who received at
least one dose of therapy. Toxicity of concurrent irinotecan,
carboplatin, and bevacizumab therapy was assessed after the
first 10 patients were treated. Expected toxicities included
myelosuppression and diarrhea. If there was any grade 4
myelosuppression in more than two of the first 10 patients,
further accrual would be stopped and a dose reduction in
chemotherapy was considered.
Because of the previously observed incidence of grade
3 or 4 hemoptysis in patients with non-small cell lung cancer,
any incidence of grade 3 or 4 hemoptysis would have been an
indication for suspension of further enrollment. In addition,
the occurrence of any other severe (grade 3 or 4) and
unexpected toxicity during treatment with bevacizumab
would result in trial suspension.
RESULTS
Patient Characteristics
Fifty-one patients were enrolled from February 2006 to
March 2007, 67% from Tennessee and 33% from Ohio,
Kentucky, Florida, and Georgia. Baseline characteristics for
all patients are described in Table 1. The median age was 66
years (range 46 to 81 years). Twenty-nine patients (57%)
were male and 22 patients were female. ECOG-PS was 0 in
17 patients (33%) and 1 in 34 patients (67%). Metastatic sites
included liver (59%), lymph nodes (51%), bone (49%), and
adrenal glands (16%).
Treatment Received
The median follow-up is 22 months (range 16–27
months). Twenty-nine (57%) patients completed six cycles of
chemotherapy and bevacizumab (median three cycles). How-
ever, only 19 patients (37%) went on to receive maintenance
bevacizumab (median three cycles). The most common rea-
sons for not receiving maintenance therapy included progres-
sive disease, intercurrent illness, physician or patient deci-
sion, and treatment-related toxicity. Four patients (8%)
completed all planned primary and maintenance therapy.
Four patients (8%) were not assessable for a response
because of treatment-related toxicity (hypertension, mucosi-
tis, diarrhea, and renal insufficiency, one patient each). All of
these patients were included in the efficacy analyses.
Response
Fifty-one patients are included in the response analysis
(Table 2). Unconfirmed complete responses were seen in 1
patient (2%) and partial responses in 42 patients (82%), for an
overall response rate of 84% (95% CI 71–93%, unconfirmed).
Two patients (4%) had stable disease, and 2 patients (4%) had
progressive disease. The median response duration was 6.4
months (95% CI 4.1–7.7 months).
TABLE 1. Baseline Characteristics
Characteristic Patients, n (%)
Age (yr)
Median 66
Range 46–81
Gender
Male 29 (57)
Female 22 (43)
ECOG performance status
0 17 (33)
1 34 (67)
Metastatic site
Bone 25 (49)
Liver 30 (59)
Lymph nodes 26 (51)
Other 11 (22)
Adrenal 8 (16)
Chest wall 1 (2)
Retroperitoneal 1 (2)
Abdominal wall 1 (2)
Location of treatment facility
Nashville site 34 (67)
Consortium sites 17 (33)
TABLE 2. Response Rates (n  51)
Response n (%)
Completea 1 (2)
Partiala 42 (82)
Stable disease 2 (4)
Progression 2 (4)
Not assessableb 4 (8)
a Unconfirmed responses.
b Not assessable due to treatment-related toxicity.
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Time to Progression and Survival
The 6-month TTP was 76% (95% CI 58%–87%)—a
52% improvement over an historical control of 50% (Fig. 2).
The median TTP was 9.13 months (95% CI 7.36–9.46
months). The median overall survival (OS) was 12.1 months
(95% CI 9.6–13.5 months; Fig. 3). One-year OS was 51%
(95% CI 9.6–13.5%), and 2-year OS was 14% (95% CI
5–26%).
Treatment-Related Toxicity
Treatment-related toxicity for each phase of treat-
ment is summarized in Tables 3 and 4. In general, the
chemotherapy and bevacizumab, and maintenance bevaci-
zumab treatment phases were well tolerated; however,
diarrhea and cytopenias were notable toxicities. Neutro-
penic fever occurred in three patients overall. The most
common (5%) grade 3/4 toxicities during chemotherapy
and bevacizumab were: neutropenia (39%), thrombocyto-
penia (22%), cardiovascular events (6%), dehydration
(10%), diarrhea (31%), fatigue (20%), hyperglycemia
(7%), hyponatremia (6%), proteinuria (6%), and pulmo-
nary symptoms (10%). The most common (5%) grade
3/4 toxicities during bevacizumab maintenance therapy
were: anemia (11%), thrombocytopenia (53%), diarrhea
(21%), dehydration (26%), fatigue (31%), hyperglycemia
(21%), hyponatremia (10%), mental status changes (11%),
pain (21%), and pulmonary symptoms (11%). No patients
experienced grade 3 or 4 bleeding (including hemoptysis)
or stroke. Two patients died due to infection that was
possibly treatment related. A third patient, who had been
responding to treatment, died of liver failure. The cause of
this acute decline was unclear. Other potential treatment-
related toxicity included: pulmonary embolism, acute renal
FIGURE 2. Time to progression (TTP). Six-month TTP was
76%, a 52% improvement over an historical control of 50%.
Median TTP was 9.13 months.
FIGURE 3. Overall survival (OS). Median OS was 12.1
months; 1- and 2-year OS were 51 and 14%, respectively.
TABLE 3. Grade 3 and 4 Toxicity During Chemotherapy
and Bevacizumab in 5% of Patients (n  51)
Toxicity Grade 3 Grade 4 Comments
Neutropenia, n (%) 16 (31) 4 (8)
Leukopenia, n (%) 10 (20) 1 (2)
Thrombocytopenia,
n (%)
5 (10) 5 (10)
Cardiovascular, n (%) 2 (4) 1 (2) Includes: MI (G4), atrial
fibrillation (G3),
decreased leftventricular
function (G3)
Dehydration, n (%) 5 (10) 0
Diarrhea, n (%) 15 (29) 1 (2)
Fatigue, n (%) 9 (18) 1 (2)
Hyperglycemia, n (%) 4 (7) 0
Hyponatremia, n (%) 2 (4) 1 (2)
Proteinuria, n (%) 3 (6) 0
Pulmonary, n (%) 3 (2) 4 (8) Includes: pneumonia (G3–1,
G4–1), dyspnea (G3–1),
asthma exacerbation
(G3–1), congestive heart
failure (G4–1), pulmonary
emboli (G4–2)
Renal failure 0 0 1 (2%)–Grade 5
TABLE 4. Grade 3 and 4 Toxicity During Maintenance
Bevacizumab in 5% of Patients (n  19)
Toxicity Grade 3 Grade 4 Comments
Anemia, n (%) 0 2 (11)
Thrombocytopenia,
n (%)
5 (26) 5 (26)
Acute Diarrhea, n (%) 4 (21) 0
Dehydration, n (%) 5 (26) 0
Fatigue, n (%) 5 (26) 1 (5)
Hyperglycemia, n (%) 4 (21) 0
Hyponatremia, n (%) 2 (11) 1 (5)
Mental status change,
n (%)
2 (11) 0 Includes: confusion (G3–1),
delirium (G3–1)
Pain, n (%) 4 (21) 0 Includes: abdominal (G3–2),
head (G3–2)
Pulmonary, n (%) 2 (11) 0 Includes: dyspnea (G3–1),
pneumonia (G3–1)
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failure, and grade 4 hypertension occurring in one patient
each. All other grade 3/4 hematologic and nonhematologic
toxicities were uncommon (5%).
DISCUSSION
Limited progress has been made over the last three
decades in the treatment of ES-SCLC. Platinum-based dou-
blet chemotherapy remains the standard first-line treatment,
resulting in a median survival of approximately 10 months.2,3
Early enthusiasm for irinotecan in SCLC treatment has only
translated into comparable survival outcomes with etopo-
side.3,4 Newer therapies are needed.3,4,14,20,21
The recent success of adding bevacizumab to standard
chemotherapy regimens in several solid tumor settings (colo-
rectal, non-small cell lung, and breast) has encouraged the
development of bevacizumab in other treatment settings,
including SCLC.5–7,11 The role of angiogenesis in SCLC is
unknown, although some preclinical models suggest this may
be a useful target.8–10 Our center previously conducted a
phase II study using bevacizumab in a maintenance role, but
found little benefit for this strategy.11 Other centers have
similarly found no benefit to a maintenance strategy using the
angiogenesis inhibitors thalidomide or vandetanib.22,23
The present trial was planned to introduce bevacizumab
earlier in treatment by administering it concurrently with
chemotherapy. The combination of irinotecan and carboplatin
was chosen as the platform regimen because of phase II
experience from our center and others, and now from phase
III trials, showing this regimen to be comparable to etoposide
and platinum, although at a cost of excess diarrhea.12–16
Toxicity was generally manageable in this trial, but
diarrhea, dehydration, and thrombocytopenia were notable.
These rates were higher than was seen in a previous trial
using a similar irinotecan and carboplatin platform regimen
(with imatinib), suggesting that bevacizumab could be adding
to this toxicity.16 The fact that some patients experienced
similar toxicity during maintenance bevacizumab alone fur-
ther supports this possibility, although some toxicity may
have been due to the cumulative effect of prior chemotherapy
(i.e., thrombocytopenia).
This trial demonstrated response rate, TTP, and sur-
vival outcomes that compare favorably with results from
larger randomized trials of chemotherapy alone.2,3 However,
these results could simply be due to patient selection or
chemotherapy alone. This trial is limited in its ability to
define bevacizumab’s impact on chemotherapy treatment.
Importantly, these results compare with other phase II
trials in ES-SCLC using bevacizumab (Table 5). In a single
arm trial by the Cancer and Leukemia Group B using cispla-
tin, irinotecan, and bevacizumab in 72 patients with newly
diagnosed ES-SCLC, the response rate, median progression-
free, median overall, and 1-year OSs were: 75%, 7.1 months,
11.7 months, and 49%, respectively.24 Similarly, in a phase II
trial of cisplatin, etoposide, and bevacizumab by Sandler et
al.25 in 64 patients, the response rate, median failure-free,
6-month failure-free, and median OSs were: 69%, 4.7
months, 33%, and 11.1 months, respectively.
In conclusion, the role of bevacizumab in the treatment
of SCLC remains unknown. This trial suggests there may be
improved efficacy, and greater toxicity, when bevacizumab is
given concurrently with irinotecan and carboplatin. However,
the potential added value of bevacizumab in the first-line
treatment of ES-SCLC can only be assessed in a randomized
trial. A randomized phase II trial comparing platinum (cis-
platin or carboplatin) and etoposide and/or bevacizumab has
recently completed accrual and may further add to our un-
derstanding of bevacizumab’s role in SCLC treatment.26
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APPENDIX
Sarah Cannon Oncology Research Consortium
Participating Sites
Tennessee Oncology, PLLC, Nashville, TN.
Florida Cancer Specialists, Fort Myers, FL.
Oncology Hematology Care, Cincinnati, OH.
Watson Clinic Center for Research, Inc., Lakeland, FL.
Northeast Georgia Medical Center, Gainesville, GA.
Consultants in Medical Oncology and Hematology, PC,
Drexel Hill, PA.
TABLE 5. Phase II Trials in ES-SCLC Using Bevacizumab
Study n Regimen ORR (%) Median TTP/PFS (mo) Median OS (mo) 1-Year OS (%)
Hanna3 331 CI vs.CE 48 vs. 44 4.1 (TTP) vs. 4.6 9.3 vs. 10.2 35 vs. 35
Eckardt2 784 CE 69 5.8 (TTP) 9.2 31
Chen27 80 CaE 50–65 NR 10 NR
Sandler25 64 CEB 69 4.7 (PFS) 11.1 NR
6 PFS 33%
Ready24 72 CIB 75 7.1 (PFS) 11.7 49
Spigel 51 CaIB 84 9.1 (TTP) 12.1 51
6 TTP 76%
B, bevacizumab; C, cisplatin; Ca, carboplatin; E, etoposide; I, irinotecan; ORR, objective response rate; TTP, time to progression; PFS,
progression-free survival; OS, overall survival; NR, not reported.
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